10-Q: Precigen Reports Third Quarter 2024 Results, Focuses on PRGN-2012

Precigen, Inc. announced its third quarter 2024 results, highlighting a strategic shift towards its PRGN-2012 program and a reduction in workforce.

Summary

• Precigen reported a net loss of $23.98 million for the third quarter of 2024, compared to a net loss of $19.79 million for the same period in 2023.
• The company's total revenues for the quarter were $0.95 million, down from $1.38 million in the third quarter of 2023.
• Operating expenses were $22.22 million, slightly down from $22.32 million in the same quarter of the previous year.
• The company incurred a net loss of $106.51 million for the nine months ended September 30, 2024, compared to a net loss of $62.85 million for the same period in 2023.
• Research and development expenses for the nine months ended September 30, 2024 were $41.31 million, up from $35.62 million in the same period of 2023.
• The company has strategically prioritized its resources towards the PRGN-2012 program, leading to a reduction of over 20% of its workforce.
• Precigen is preparing for a potential launch of PRGN-2012 in 2025, pending regulatory approval.
• The company completed the shutdown of its ActoBio subsidiary operations, incurring non-cash impairment charges of $34.5 million.
• A public offering of common stock in August 2024 resulted in net proceeds of $30.88 million.
• As of September 30, 2024, the company had $24.73 million in cash and cash equivalents and $3.91 million in short-term investments.

Sentiment

Score: 4

Explanation: The document presents a mixed picture. While there is a clear strategic focus on PRGN-2012 and progress towards a BLA submission, the financial results are concerning, with increased losses, decreased revenue, and substantial doubt about the company's ability to continue as a going concern. The workforce reduction and shutdown of ActoBio also contribute to a negative sentiment.

Positives

• The company is focusing on its lead program, PRGN-2012, which has Breakthrough Therapy and Orphan Drug designations.
• The FDA has agreed that the Phase 1/2 clinical trial of PRGN-2012 will serve as pivotal for the purpose of filing an accelerated approval request for licensure.
• The company is accelerating commercial readiness efforts for a potential launch of PRGN-2012 in 2025.
• The company has completed enrollment in the Phase 1b trial for PRGN-3006 in AML and is planning for an end of Phase 1b meeting with the FDA.
• The company has raised $30.88 million in net proceeds from a public offering of its common stock in August 2024.

Negatives

• The company reported a net loss of $23.98 million for the third quarter of 2024, an increase from the $19.79 million loss in the same period of 2023.
• Total revenues decreased to $0.95 million in the third quarter of 2024, down from $1.38 million in the third quarter of 2023.
• The company has paused enrollment in PRGN-3005 and PRGN-3007 UltraCAR-T clinical trials.
• The company has shut down its ActoBio subsidiary operations, incurring a $34.5 million non-cash impairment charge.
• The company has incurred operating losses since its inception and expects operating losses and negative cash flows from operations to continue for the foreseeable future.
• The company's current cash and investments position is not sufficient to fund the company's planned operations through one year after the date the interim financial statements are issued.
• There is substantial doubt about the company's ability to continue as a going concern.

Risks

• The company's ability to fund its operations is dependent on raising additional capital.
• There is no assurance that new financing or other transactions will be available on commercially acceptable terms.
• The company may be required to delay, reduce the scope of, or eliminate some or all of its operations if it is unable to obtain additional capital.
• The company is subject to risks associated with early-stage research and development, including dependence on key individuals and intellectual property, competition, and technical risks.
• The company's common stock is subject to delisting from the Nasdaq Global Select Market if it does not meet continued listing requirements.
• The company is involved in ongoing legal proceedings, the outcomes of which are uncertain.

Future Outlook

The company plans to submit a BLA for PRGN-2012 under an accelerated approval pathway in the fourth quarter of 2024 and is preparing for a potential launch in 2025. The company will continue the acceleration of commercial readiness efforts for a potential launch in 2025. The company is also exploring a number of potential opportunities for future liquidity.

Management Comments

• The company is strategically prioritizing its clinical portfolio and streamlining its resources to focus on the potential commercialization of PRGN-2012.
• The company is minimizing UltraCAR-T spend and focusing on strategic partnerships to further advance UltraCAR-T programs.
• The company is continuing PRGN-2009 Phase 2 clinical trials under a cooperative research and development agreement with the National Cancer Institute.
• The company has completed the shutdown of its ActoBio subsidiary operations.
• The company is exploring a number of potential opportunities for future liquidity.

Industry Context

The strategic shift towards PRGN-2012 reflects a trend in the biopharmaceutical industry to focus on lead programs with near-term commercial potential. The company's decision to pause other clinical trials and reduce workforce is indicative of the challenges faced by many biotech companies in managing resources and prioritizing development efforts. The focus on precision medicine and gene therapies aligns with broader industry trends in personalized healthcare.

Comparison to Industry Standards

• The company's decision to focus on PRGN-2012 is similar to other biotech companies that have streamlined their pipelines to focus on lead assets with the highest probability of success.
• The workforce reduction is a common strategy in the biotech industry to conserve cash and extend the runway for key programs.
• The company's cash burn rate is higher than some of its peers, which is a concern given the substantial doubt about its ability to continue as a going concern.
• The company's reliance on external funding is similar to many early-stage biotech companies, but the lack of committed funding sources is a significant risk.
• The company's focus on gene therapy and immuno-oncology is in line with current industry trends, but the competition in these areas is intense.
• The company's decision to shut down ActoBio is similar to other companies that have divested non-core assets to focus on their primary business.

Legal Proceedings

• The company is involved in ongoing legal proceedings, the outcomes of which are uncertain.

Related Party Transactions

• In January 2023, related parties and their affiliates purchased 11,517,712 shares of common stock in a public offering.
• In August 2024, related parties and their affiliates purchased 23,588,234 shares of common stock in a public offering.

Stakeholder Impact

• Shareholders face the risk of further dilution and potential delisting of the company's stock.
• Employees have been impacted by the workforce reduction.
• Customers of Exemplar may experience changes in service offerings.
• Suppliers and creditors may be impacted by the company's financial instability.

Next Steps

• The company plans to submit a BLA for PRGN-2012 in the fourth quarter of 2024.
• The company will continue the confirmatory clinical trial for PRGN-2012.
• The company will continue acceleration of commercial readiness efforts for a potential launch of PRGN-2012 in 2025.
• The company is planning for an end of Phase 1b meeting with the FDA for PRGN-3006.
• The company will continue to explore potential opportunities for future liquidity.

Key Dates

Keywords

PRGN-2012, AdenoVerse, UltraCAR-T, RRP, Biopharmaceuticals, Clinical Trials, BLA, ActoBio, Exemplar, Financial Results, Workforce Reduction, Capital Raise